Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc (MDP – Research Report), with a price target of C$6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Martin PhD has given his Buy rating due to a combination of factors including Medexus Pharmaceuticals Inc’s recent financial performance and promising product developments. The company’s revenues and EBITDA have met expectations, indicating stable financial health.
Additionally, the early signs from the launch of Grafapex are positive, suggesting potential for future growth. These elements together contribute to a favorable outlook for Medexus, justifying the Buy recommendation.
In another report released on June 27, Raymond James also maintained a Buy rating on the stock with a C$8.00 price target.
MDP’s price has also changed slightly for the past six months – from C$3.300 to C$3.150, which is a -4.55% drop .